Medicenna Will Present Cancer Drug Data in Phoenix
New clinical trial results for the immunotherapy drug MDNA11 will be shared with the medical community in November.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Do you trust the information provided by pharmaceutical companies regarding new clinical trial results?
Medicenna Therapeutics is scheduled to present data from its Phase 1/2 ABILITY-1 clinical trial at the Society for Immunotherapy of Cancer 2026 Annual Meeting. The presentation, set for November 7, 2026, in Phoenix, highlights early findings in advanced gastrointestinal, endometrial, and melanoma cancers.
Why it matters
This presentation offers insights into how the immunotherapy candidate MDNA11 performs both as a standalone treatment and in combination with other therapies for patients with advanced malignancies. The findings specifically address outcomes for individuals with diseases that have proven resistant to standard immune checkpoint inhibitor treatments.
Researchers are sharing preliminary Phase 1/2 data from the ABILITY-1 trial, which utilizes expansion cohorts to evaluate the therapeutic drug. The study specifically includes patients with biomarker-enriched gastrointestinal malignancies, focusing on ICI-refractory disease states.
The players
Medicenna Therapeutics
A developer of cytokine-based therapies for cancer and autoimmune conditions based in Toronto and Houston.
Society for Immunotherapy of Cancer
A professional organization that advances the science and application of cancer immunotherapy through meetings and research dissemination.
The details
MDNA11 is a cytokine therapy designed by Medicenna Therapeutics to modulate the immune system against cancer cells. The trial evaluates the drug in expansion cohorts to measure efficacy in solid tumors that are often difficult to treat. By targeting specific biomarkers in advanced or metastatic cancers, the therapy aims to overcome resistance seen in existing immunotherapies.
Timeline
October 5, 2026: Medicenna announced the upcoming data presentation.
November 7, 2026: Medicenna will present study data at the SITC meeting.
Health Landscape
This development reflects the broader trend of testing cytokine-based therapies to improve outcomes in solid tumors. It represents a significant step in the ongoing effort to manage cancers that have historically failed to respond to conventional immune checkpoint inhibitor treatments.
Patients with advanced or metastatic malignancies may find this research relevant as a topic to discuss with their oncology team. It is essential to consult your physician to understand how such trial-based therapies fit into your specific treatment plan and care decisions.
The takeaway
The upcoming presentation provides a look at new treatment options for patients with refractory gastrointestinal cancers. Keep an eye on clinical trial progress if you or a loved one are managing advanced-stage disease and exploring new immunotherapy avenues with your medical provider.
Further reading
For more on the latest research and clinical approaches in this field, visit our Cancer section.
Live Poll
Do you trust the information provided by pharmaceutical companies regarding new clinical trial results?
